iBio Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Tables)

Earnings (Loss) Per Common Share (Tables)

12 Months Ended

Jun. 30, 2023

Earnings (Loss) Per Common Share [Abstract]

Schedule of Earnings (loss) Per Share, Basic and Diluted

The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):


	Year Ended
	June 30,
	2023		2022
Basic and diluted numerator:

Net loss attributable to iBio, Inc. from continuing operations	$	(29,311)	$	(29,512)
Preferred stock dividends – iBio CMO Preferred Tracking Stock		—		(88)
Net loss available to iBio, Inc. stockholders from continuing operations	$	(29,311)	$	(29,600)

Net loss available to iBio, Inc. stockholders from discontinued operations	$	(35,699)	$	(20,791)

Net loss available to iBio, Inc. stockholders - total	$	(65,010)	$	(50,391)

Basic and diluted denominator:

Weighted-average common shares outstanding		12,245		8,721

Per share amount - continuing operations	$	(2.39)	$	(3.39)
Per share amount - discontinued operations	$	(2.92)	$	(2.39)
Per share amount - total	$	(5.31)	$	(5.78)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

In Fiscal Years 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of June 30, 2023 and 2022, shares issuable which could potentially dilute future earnings included were as follows:


	June 30,
	2023	2022

	(in thousands)
Stock options	292	622
Restricted stock units	248	51
Warrants	5,871	21
Series 2022 Preferred	—	*
Shares excluded from the calculation of diluted loss per share	6,411	694

* Less than 1,000